On December 16, 2024, Chrystal Jensen, Chief Legal Officer at Cerus Corp, executed a sale of 16,667 shares of Cerus Corp (CERS, Financial). Following this transaction, the insider now holds 457,578 shares of the company. The details of this transaction can be found in the SEC Filing.
Cerus Corp is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's products are designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens in donated blood components.
Over the past year, Chrystal Jensen has sold a total of 68,618 shares and has not made any purchases. The insider transaction history for Cerus Corp indicates there have been 4 insider buys and 13 insider sells over the same period.
On the day of the recent sale, shares of Cerus Corp were trading at $1.71, giving the stock a market cap of $334.288 million. The stock's GF Value is estimated at $2.93, resulting in a price-to-GF-Value ratio of 0.58. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
